Trial reportThe American journal of gastroenterology2018
Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment.
Trial report in The American journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 52 citations in OpenAlex.
- Effect of oat or rice flour on pulse-induced gastrointestinal symptoms and breath hydrogen in subjects sensitive to pulses and controls - a randomised cross-over trial with two parallel groups.The British journal of nutrition · 2022Trial
- The Effects of Fermentable Oligo-, Di-, and Monosaccharides and Polyols on Dyspeptic Symptoms: A Systematic Review and Meta-Analysis of Clinical Trials.Health science reports · 2026Review
- Association of Carbohydrate Consumption and Bloating in Individuals With Different FTO Genotypes.Molecular nutrition & food research · 2026Article
- Multi-environment evaluation of raffinose-family oligosaccharide content in diverse dry bean varieties and their reduction upon canning.Journal of the science of food and agriculture · 2026Article
- FODMAP-Targeting Digestive Enzyme Blend for Management of Gastrointestinal Symptoms: A "Real-World" Pre-Post Intervention Cohort Study.Gastro hep advances · 2026Article
- Innovative concepts in diet therapies in disorders of gut-brain interaction.JGH open : an open access journal of gastroenterology and hepatology · 2024Review
- Gastrointestinal Symptoms and Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Sources in Schoolchildren-A Pilot Study.Children (Basel, Switzerland) · 2024Article
- Evolution, adaptation, and new applications of the FODMAP diet.JGH open : an open access journal of gastroenterology and hepatology · 2024Review
- Safety and Tolerability of Microbial Inulinase Supplementation in Healthy Adults: A Randomized, Placebo-Controlled Trial.Gastro hep advances · 2024Article
- Disruption of the microbiota-gut-brain axis is a defining characteristic of the α-Gal A (-/0) mouse model of Fabry disease.Gut microbes · 2023Article
- Constipation-Predominant Irritable Bowel Syndrome (IBS-C): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms.Nutrients · 2023Review
- Microbial inulinase promotes fructan hydrolysis under simulated gastric conditions.Frontiers in nutrition · 2023Article
- Application of The FODMAP Diet in a Paediatric Setting.Nutrients · 2022Review
- How to Implement the 3-Phase FODMAP Diet Into Gastroenterological Practice.Journal of neurogastroenterology and motility · 2022Review
- Presentation and Characteristics of Abdominal Pain Vary by Irritable Bowel Syndrome Subtype: Results of a Nationwide Population-Based Study.The American journal of gastroenterology · 2020Article
- Food Intolerances.Nutrients · 2019Review
- Update on Dietary Management of Childhood Functional Abdominal Pain Disorders.Gastroenterology clinics of North America · 2018Review
- The gut microbiome and irritable bowel syndrome.F1000Research · 2018Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesGalacto-oligosaccharides (GOS) are dietary FODMAPs (fermentable carbohydrates) associated with triggering gastrointestinal symptoms in patients with irritable bowel syndrome (IBS). This randomized, double-blind, placebo-controlled, cross-over trial aimed to assess whether oral α-galactosidase co-ingestion with foods high in GOS and low in other FODMAPs would reduce symptoms.
methodsPatients meeting the Rome III criteria for IBS who were hydrogen-producers on breath testing were recruited. Participants were treated with full-dose (300 GALU (galactosidic units) α-galactosidase) and half-dose enzyme (150 GALU α-galactosidase), and placebo (glucose) in a random order with ≤14 days washout between arms. Following a 3-day low FODMAP run-in period, participants consumed provided diets high in GOS for a further 3-days. Gastrointestinal symptoms were measured daily using a 100 mm visual-analogue-scale, and breath samples taken hourly on the second last day with hydrogen content analysed as area-under-the-curve.
resultsThirty-one patients with IBS (20 IBS-D, 4 IBS-C, 7 IBS-M) completed the study. The addition of high GOS foods resulted in a significant increase in overall symptoms with 21 patients exhibiting GOS-sensitivity (>10 mm increase for overall symptoms). Of those, full-dose enzyme reduced overall symptoms (median 24. 5(IQR 17.5-35.8) vs. 5.5(1.5-15.0) mm; P=0.006) and bloating (20.5(9.5-42.0) vs. 6.5(2.0-15.8); P=0.017). Breath hydrogen production was minimal with no differences seen between placebo and full-dose (P=0.597).
conclusionsOral α-galactosidase taken with high GOS foods provides a clinically significant reduction in symptoms in GOS-sensitive individuals with IBS. This strategy can be translated into practice to improve tolerance to high GOS foods as an adjunct therapy to the low FODMAP diet.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.